Patents Assigned to Yamanouchi Pharmaceutical Co., Ltd.
-
Publication number: 20050100602Abstract: [Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting, there is a problem to provide a sustained-release pharmaceutical composition in which efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited. [Means for Resolution] A sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and, when dissolution test is carried out according to Japanese Pharmacopoeia Dissolution Test Method 2, the tamsulosin release after 7 hours from the start of the dissolution is about 20 to about 85%.Type: ApplicationFiled: May 10, 2004Publication date: May 12, 2005Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Kazuhiro Sako, Toyohiro Sawada, Keiichi Yoshihara, Hiroyuki Kojima
-
Publication number: 20050100603Abstract: [Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting at present, it is needed to provide a sustained-release pharmaceutical composition in which the efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited in the dosage and it is also needed to provide a method for administration of tamsulosin hydrochloride in which the adverse reactions accompanied by therapy or prevention on the basis of an ?1 receptor blocking action are reduced.Type: ApplicationFiled: May 10, 2004Publication date: May 12, 2005Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Kazuhiro Sako, Toyohiro Sawada, Hiromu Kondo, Keiichi Yoshihara, Hiroyuki Kojima
-
Publication number: 20050100607Abstract: The present invention relates to a method for improving adsorption on the gastrointestinal mucous layers of one or more selected from polyethylene glycol, polyethylene oxide, and polyoxyethylene polypropylene copolymer wherein the average number of repeating oxyethylene units of one ethylene oxide chain length is 17 or greater. It is possible to enhance pharmacological effects by using the present invention with drugs that have anti-H. pylori activity.Type: ApplicationFiled: September 26, 2003Publication date: May 12, 2005Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Keiichi Yoshihara, Kazuhiro Sako
-
Patent number: 6877598Abstract: A transfer apparatus transfers tablets ejected from a tableting machine to a container. The transfer apparatus includes a first chute, a cloth chute which serves as a buffer disposed at one end of the first chute, a winding apparatus for lifting the free end of the cloth chute, a bucket for receiving the tablets from the cloth chute, and a swiveling lift for moving the bucket. Because the formed pieces are not transported directly from the first chute to the bucket, but are first received within the buffer and then transported to the container, occurrence of cracking or chipping of the formed pieces can be prevented and high quality can also be maintained through minimizing the impact on the formed pieces which would otherwise occur during transporting.Type: GrantFiled: October 30, 2002Date of Patent: April 12, 2005Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Minoru Hattori, Keizo Baba
-
Patent number: 6878525Abstract: A cDNA encoding a novel LTC4 receptor has been isolated. Provision of the novel protein, an LTC4 receptor, enabled binding experiments using the LTC4. By screening for compounds that modulate LTC4 receptor activity based on these binding experiments, development of drugs targeting the LTC4 receptor becomes possible.Type: GrantFiled: September 13, 2000Date of Patent: April 12, 2005Assignees: Yamanouchi Pharmaceutical Co, Ltd., Helix Research InstituteInventors: Jun Takasaki, Masazumi Kamohara, Mitsuyuki Matsumoto, Tetsu Saito, Tohru Sugimoto, Toshio Ota, Takao Isogai, Tetsuo Nishikawa, Yuri Kawai
-
Patent number: 6872405Abstract: The present invention relates to a quick-disintegrating tablet in the buccal cavity comprising a drug, a diluent, and a saccharide with a relatively lower melting point than the drug and the diluent, which is obtained by uniformly mixing the saccharide with a low melting point in the tablet so that a bridge will be formed between said drug and/or said diluent particles by the product of melting and then solidification of this saccharide with a low melting point.Type: GrantFiled: May 8, 2002Date of Patent: March 29, 2005Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Yuuki Takaishi, Takao Mizumoto, Yoshinori Masuda
-
Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems
Publication number: 20050054026Abstract: The present invention relates to conjugates of a lipid, substrate peptide of an enzyme secreted from the cells of mammals, including humans, and a water-soluble polymer that can be used as colloidal carriers and the like of tissue-specific drug delivery systems, methods of producing these conjugates, peptide-water-soluble polymer conjugates optionally having protective groups that are useful as the intermediates of these conjugates, colloidal carriers made from these conjugates, and tissue-specific drug delivery systems that use these colloidal carriers.Type: ApplicationFiled: January 9, 2004Publication date: March 10, 2005Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Maeda Atsushi, Akira Takagi, Katsumi Saito, Noboru Yamashita, Tatsnobu Yoshioka -
Patent number: 6861070Abstract: A therapeutic agent for voiding dysfunction associated with neurogenic bladder where said agent contains tamsulosin or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 23, 1999Date of Patent: March 1, 2005Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventor: Kouji Yoshinaga
-
Publication number: 20050031587Abstract: The present invention proposes a method of inducing both vaccine antigen-specific antibody in blood and vaccine antigen-specific antibody secreted at the mucosal surface using vaccine antigen and adjuvant of said vaccine antigen.Type: ApplicationFiled: September 29, 2003Publication date: February 10, 2005Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Yuuki Tsutsui, Kiyo Nakanishi, Shunsuke Watanabe, Shigeo Takemura
-
Publication number: 20050026981Abstract: This invention is aimed to provide a stabilized formulation of ramosetron or a pharmaceutically acceptable salt thereof under a temperature/humidity condition, especially at a low content and relates to a stable oral solid drug composition of ramosetron or a pharmaceutically acceptable salt thereof, which is characterized by containing one or two or more members selected from the group consisting of an aliphatic carboxylic acid or an ester thereof, a hydroxycarboxylic acid or an ester thereof, an acidic amino acid, an enolic acid, an aromatic carboxyl compound or an ester thereof, and a carboxyl group-containing high-molecular substance, and to a stabilization method of the same. Also, this invention relates to a therapeutic agent of diarrhea-predominant irritable bowel syndrome containing from 0.002 to 0.02 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt as an active ingredient.Type: ApplicationFiled: August 27, 2004Publication date: February 3, 2005Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Akio Sugihara, Katsuhiro Masaki, Takehiko Yasuji
-
Patent number: 6838457Abstract: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.Type: GrantFiled: June 10, 2003Date of Patent: January 4, 2005Assignees: Yamanouchi Pharmaceutical Co., Ltd., Ludwig Institute for Cancer Research, Imperial Cancer Research Technology Ltd.Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, Ken-Ichi Kawaguchi, Tomonobu Koizumi, Mayumi Yamano, Koyo Matsuda, Minoru Okada, Mitsuaki Ohta
-
Enteric sustained-release fine particles of tamsulosin and its salt and manufacturing method thereof
Publication number: 20040253309Abstract: The present invention relates to enteric sustained-release fine particles of tamsulosin or its salt that can be contained in tablets that disintegrate in the buccal cavity and a manufacturing method thereof.Type: ApplicationFiled: January 27, 2004Publication date: December 16, 2004Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Yoji Tanijiri, Akira Ito, Hiroya Sugao, Tetsuya Tamura, Mare Nishura, Shigeru Yamazaki, Takao Mizumoto -
Patent number: 6828101Abstract: The present invention relates to a novel potassium channel protein expressed exclusively in the brain, a gene encoding this protein, a vector containing this gene, a host cell containing this vector, and so on. A typical method for obtaining the potassium channel protein of the present invention; mRNA is extracted from human cells or tissue capable of producing the potassium channel protein of the present invention. Then use is made of two primers between which the channel protein mRNA or a part of the mRNA region is located by using the thus extracted mRNA as a template. By carrying out a reverse transcriptase-polymerase chain reaction (to be referred to as RT-PCR hereinafter), the channel protein cDNA or a part thereof can be obtained. Thereafter, the channel protein can be produced by integrating the thus obtained novel potassium channel cDNA or a part of the same into an appropriate expression vector and then effecting its expression in a host cell.Type: GrantFiled: October 1, 2001Date of Patent: December 7, 2004Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Akira Miyake, Shinobu Mochizuki, Hiromichi Yokoi
-
Patent number: 6822098Abstract: An ester or amide derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof. Particularly, an ester or amide derivative of 4-oxo-1,4-dihydroqunoline-2-carboxylic acid represented by the general formula (I′) or (I″), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 28, 2003Date of Patent: November 23, 2004Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Jun-ichi Kazami, Masato Watanabe, Takuya Hirata
-
Publication number: 20040213845Abstract: The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) and wherein at least the above-mentioned specific size controlling agent is uniformly dispersed in the above-mentioned polyethylene oxide, a controlled-release pharmaceutical composition containing this sized product, and a method of manufacturing a controlled-release pharmaceutical composition containing this sized product.Type: ApplicationFiled: December 23, 2003Publication date: October 28, 2004Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Akio Sugihara, Kazuhiro Sako, Toyohiro Sawada
-
Publication number: 20040214818Abstract: The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.Type: ApplicationFiled: May 19, 2004Publication date: October 28, 2004Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD., MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNGInventors: Takahiko Tobe, Takashi Sugane, Wataru Hamaguchi, Itsuro Shimada, Kyoichi Maeno, Junji Miyata, Tetsuya Kimizuka, Takeshi Suzuki, Atsuyuki Kohara, Takuma Morita, Michael Arlt, Hartmut Greiner
-
Patent number: 6808899Abstract: This invention belongs to the genetic engineering field, and provides novel G protein-coupled receptor family proteins SREB1, SREB2 and SREB3 expressed in the central nervous system, genes coding for these proteins, screening methods using these proteins and so on. As one of the methods for obtaining the G protein-coupled receptor proteins of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.Type: GrantFiled: December 13, 2002Date of Patent: October 26, 2004Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Mitsuyuki Matsumoto, Toru Sugimoto, Jun Takasaki, Masazumi Kamohara, Tetsu Saito, Masato Kobayashi
-
Patent number: 6803054Abstract: The present invention relates to a quick disintegrating tablet in buccal cavity, comprising: a mixture, comprising a drug, a sugar (A), and an amorphous sugar (B), and after it is forming a tablet, it is humidified and dried. In particularly, the present invention relates to a quick disintegrating tablet in buccal cavity comprising: a mixture; comprising a drug, a sugar (A), and an amorphous sugar (B) which an amorphous-forming sugar in crystalline state is dissolved in a medicinally permitted solvent, the amorphous sugar is obtained from this solution by removing the solvent, and after it is forming a tablet, and it is humidified and dried. The tablet in the present invention is to provide stability against moisture at preserved, because the amorphous sugar changed to the crystalline state in a nonreversible reaction after it is humidified and dried in a manufacturing process.Type: GrantFiled: June 2, 2003Date of Patent: October 12, 2004Assignees: Yamanouchi Pharmaceutical Co., Ltd., Yamanouchi Pharma Technologies, Inc.Inventors: Takao Mizumoto, Yoshinori Masuda, Atsushi Kajiyama, Masahiro Yanagisawa, Janaki Ram Nyshadham
-
Patent number: 6797706Abstract: A nitrogen-containing six-membered heterocyclic compound having substituents —X—A—R3, —N(R1)-(Ph substituted by R2), and —CONH2, a salt thereof, a prodrug thereof, and a Syk inhibitor containing the same as an active ingredient. (In the formula, A: a (substituted) lower alkylene, a (substituted) arylene, or the like; X: NR4, CONR4, NR4CO, O, or S; R1, R4: H, a lower alkyl, —CO-lower alkyl, or —SO2-lower alkyl; R2: H, a (substituted) lower alkyl, —O-lower alkyl, —S-lower alkyl, —O-aryl, nitro, cyano, or the like; R3: —CO2H, —CO2-lower alkyl, -lower alkylene-CO2H, —NH2, -alkylene-NH2 or the like.Type: GrantFiled: December 10, 2001Date of Patent: September 28, 2004Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hiroyuki Hisamichi, Souichirou Kawazoe, Kazuhito Tanabe, Atsushi Ichikawa, Akiko Orita, Takayuki Suzuki, Kenichi Onda, Makoto Takeuchi
-
Publication number: 20040184995Abstract: The present invention provides marked results in that it is possible to present by a simple method a dry powder inhalation for pulmonary delivery that is made from a biologically active substance in crystal form and a biocompatible, electrostatic aggregation-inhibiting substance and that has excellent safety, stability, and pulmonary delivery performance.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Masataka Katsuma, Hitoshi Kawai, Takao Mizumoto